| 0 (0%) | 09-01 17:54 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.34 | 1-year : | 7.41 |
| Resists | First : | 5.43 | Second : | 6.34 |
| Pivot price | 5.13  |
|||
| Supports | First : | 4.56 | Second : | 4.03 |
| MAs | MA(5) : | 5.03 |
MA(20) : | 4.98 |
| MA(100) : | 4.93 |
MA(250) : | 5.59 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 39.5 |
D(3) : | 55.6 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 10.07 | Low : | 3.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMRX ] has closed below the lower bollinger band by 5.5%. Bollinger Bands are 56.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5 - 5.02 | 5.02 - 5.04 |
| Low: | 4.77 - 4.81 | 4.81 - 4.83 |
| Close: | 4.8 - 4.85 | 4.85 - 4.89 |
Sun, 30 Aug 2026
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Thu, 27 Aug 2026
Understanding the Setup: (IMRX) and Scalable Risk - Stock Traders Daily
Thu, 27 Aug 2026
H.C. Wainwright Maintains Immuneering(IMRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wed, 26 Aug 2026
FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan
Tue, 25 Aug 2026
Immuneering (IMRX) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Wed, 15 Jul 2026
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 65 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 55.6 (%) |
| Shares Short | 15,400 (K) |
| Shares Short P.Month | 15,030 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.95 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -52.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -5.22 |
| PEG Ratio | 0 |
| Price to Book value | 1.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|